### 1 ANALYSIS OF IMMUNE ESCAPE VARIANTS FROM ANTIBODY-BASED THERAPEUTICS AGAINST 2 COVID-19.

- 3
- 4 Daniele Focosi<sup>1,#</sup>
- 5 Fabrizio Maggi<sup>2,3</sup>
- 6 Massimo Franchini<sup>4</sup>
- 7 Scott McConnell<sup>5</sup>
- 8 Arturo Casadevall<sup>5</sup>
- 9
- <sup>1</sup>North-Western Tuscany Blood Bank, Pisa University Hospital, Pisa, Italy.
- <sup>2</sup>Department of Medicine and Surgery, University of Insubria, Varese, Italy.
- 12 fabrizio.maggi63@gmail.com
- <sup>3</sup>Laboratory of Microbiology, ASST Sette Laghi, Varese, Italy.
- 14 <sup>4</sup>Division of Transfusion Medicine, Carlo Poma Hospital, 46100 Mantua, Italy;
- 15 massimo.franchini@asst-mantova.it
- <sup>5</sup>Department of Medicine, Johns Hopkins School of Public Health and School of Medicine, Baltimore,
- 17 MD, USA; acasade1@jhu.edu; smcconn8@jhu.edu
- 18
- <sup>#</sup>corresponding author: via Paradisa 2, 56124 Pisa, Italy. E-mail: <u>daniele.focosi@gmail.com</u>
- 20
- 21 Word count: abstract 108; body 4370.
- 22 **Keywords**: SARS-CoV-2; COVID-19; Spike; convalescent plasma; viral clearance.; Q493R; E484K;
- 23 deletions
- Abbreviations: nAb : neutralizing antibodies; CCP : COVID19 convalescent plasma; PSM : propensity
   score-matched; RCT : randomized controlled trials.
- 26 **Author contributions**: D.F. conceived the manuscript; F.M. analyzed the literature; S.M. provided the
- figure and revised the final version; A.C. and M.F. revised the final version. All authors approved the final version.
- 29

#### 30 Abstract

31 Accelerated SARS-CoV-2 evolution under selective pressure by massive deployment of neutralizing 32 antibody-based therapeutics is a concern with potentially severe implications for public health. We 33 review here reports of documented immune escape after treatment with monoclonal antibodies 34 and COVID19 convalescent plasma (CCP). While the former is mainly associated with specific single 35 amino acid mutations at residues within the receptor-binding domain (e.g., E484K/Q, Q493R, and 36 S494P), the few cases of immune evasion after CCP were associated with recurrent deletions within 37 the N-terminal domain of Spike protein (e.g,  $\Delta$ HV69-70,  $\Delta$ LGVY141-144 and  $\Delta$ AL243-244). 38 Continuous genomic monitoring of non-responders is needed to better understand immune escape 39 frequencies and fitness of emerging variants.

40

41

#### 43 Introduction

SARS-CoV-2 Spike protein is the target of neutralizing antibody (nAb)-based therapeutics. Control of 44 45 the COVID19 pandemic is being hampered by continued evolution of SARS-CoV-2, which includes 46 mutations in the Spike protein that can affect immunogenicity and antibody-mediated 47 neutralization. Evolutionary modeling suggests that SARS-CoV-2 strains harboring 1-2 deleterious 48 mutations naturally exist, and their frequency increases steeply under positive selection by 49 monoclonal antibodies (mAb) and vaccines [1]. In 2% of COVID cases, SARS-CoV-2 variants with 50 multiple mutations occur, including in the Spike glycoprotein, which can become the dominant 51 strains in as little as one month of persistent in-patient virus replication [2]. While mutations can 52 occur as a natural phenomenon of SARS-CoV-2 RNA replication and editing, the pace of mutagen 53 emergence can also be affected by small-chemical antivirals (e.g. remdesivir [3] or molnupiravir [4]). 54 Since antibody-based therapies targeting the spike protein would also put selective pressure on 55 SARS-CoV-2, it is reasonable to assume that widespread deployment of nAb-based therapeutics 56 could accelerate Spike immune escape by selecting for variants resist neutralization.

57 Mutations that confer in vitro resistance to therapeutic anti-Spike mAbs have been characterized 58 with various methods, and are informative about treatment-emergent immune escape. Deep 59 mutational scanning (DMS) predicts protein expression, ACE2 binding, and mAb binding [5]. The 60 method was first deployed with yeast display libraries [6], then evolved to phage display libraries (https://jbloomlab.github.io/SARS-CoV-2-RBD\_MAP\_clinical\_Abs/) [44] and finally mammalian cell 61 62 surface display [7]. nAb binding is common within the fusion peptide and in the linker region before 63 heptad repeat (HR) region 2. The complete escape maps forecast SARS-CoV-2 mutants emerging 64 during treatment with mAbs, and allow the design of escape-resistant nAb cocktails. Complete map 65 of SARS-CoV-2 RBD mutations that escape bamlanivimab and its cocktail with etesevimab have been 66 generated [8, 9].

Although DMS was also applied to polyclonal antibodies in COVID19 convalescent plasma (CCP) [10], 67 68 the problem is much more complex such that it is almost impossible to identify escape mutations in 69 CCP or vaccinee elicited sera, given the huge heterogeneity in antibody response among CCP donors 70 and vaccinees, respectively. In vitro, continuous passaging of SARS-CoV-2 in the presence of a CCP unit with nAb titer >1:10<sup>4</sup> led to  $\Delta$ F140 Spike mutation at day 45, followed by E484K at day 73, and 71 72 an insertion in the N-terminal domain (NTD): these accumulating mutations led to complete immune 73 escape [11]. Similarly, K417N, E484K, and N501Y mutations were selected when pseudotyped SARS-CoV-2 was cultured in the presence of vaccine-elicited mAbs [12]. Although some have speculated 74 75 that the large-scale use of CCP for COVID-19 could have played a role in the emergence of variants 76 there is no evidence for such an effect and the most likely explanation for regular emergence of 77 variants has been huge number of affected individuals since each infection case provides a natural 78 opportunity for variant creation [13].

*In vivo*, while intra-host SARS-CoV-2 mutation development is typically very low [14], faster mutation rates (referred as "accelerated evolution") have been found in longitudinal studies of immunodeficient patients who had persistent SARS-CoV-2 infections for several months and were treated with nAb-based therapeutics. In this study we analyze and compare the available mutational data from SARS-CoV-2 under *in vitro* and *in vivo* selection and demonstrate that mAb and polyclonal (CCP) therapies elicit different types of mutational patterns.

85

#### 86 Methods

We mined PubMed (which also indexes the bioRxiv and medrXiv preprint servers) for keywords related to COVID19 ("COVID19", "SARS-CoV-2"), immune escape ("immune escape", "treatmentemergent resistance") and nAb-based therapeutics ("convalescent plasma", "casirivimab", "imdevimab", "bamlanivimab", etesevimab", "sotrovimab, "regdanvimab") both *in vitro* and *in vivo*. Clinical cases were annotated for eventual underlying immune deficiency, concurrent treatments and outcome. Figure 1 reports the study selection process according to PRISMA 2020 guidelines [15].

93 The 3D structural coordinates of the full Spike protein (PDBID 6VXX; residues 27-1252) [16] and the 94 receptor binding domain (PBDID 7BWJ; residues 319-529) [17], solved by cryo-electron microscopy 95 and X-ray crystallography, respectively, were used to map mutational positions of interest. Mapping on the full Spike was used to illustrate the diverse set of mutations throughout the Spike 96 97 glycoprotein, while the mutations localized to the RBD were illustrated using the more complete 98 structural model obtained through crystallography. The mutations identified in each condition of in 99 vivo or in vitro selection were tabulated and highlighted on the structures using color coding with 100 PyMOL [18].

101

### 102 Results

103 Our literature search revealed 32 papers that were then manually inspected to determine whether 104 they included relevant information that was then retrieved, evaluated and organized into Tables.

Table 1 summarizes Spike protein mutations associated with *in vitro* resistance to mAbs targeting
 this protein. These mutations were used to filter clinical case reports of treatment resistance for
 evidence of immune escape (Table 2).

Table 3 summarizes Spike mutations found in clinical cases after CCP treatment, where, immune
escape can be hypothesized to have occurred based on treatment failure, with the caveat that there
is no definitive proof of immune escape due to heterogeneity of the (uncharacterized) polyclonal
response.

Table 4 summarizes data from reports within-host clonal evolution within immunosuppressedpatients not treated with nAb-based therapeutics.

114Figure 2 depicts the Spike RBD mutations of concern for mAb binding detected in vitro and in vivo115andtheSpikemutationsdetectedafterCCPusage.

**Table 1**. Spike mutations associated with clinically-approved mAb resistance *in vitro*. Mutations conferring resistance to both mAbs within the cocktail are

# 117 underlined.

manufacturer	cocktail brand name	active ingredient (brand name)	Spike mutations associated with <i>in vitro</i> resistance	ref
Eli Lilly (AbCellera/	n.a.	etesevimab (LyCoV016, CB6, JS016, LY3832479)	K417N/T, N460I, I472D, E484K, G485P, <u>Q493R/K</u>	[8, 9, 19]
unsin)		bamlanivimab (LY-CoV555, LY3819253)	L452R, E484K, G485P, <u>Q493R/K</u> , S494P	
Regeneron/Roche	REGN-COV2	imdevimab (REGN10987)	<u>E406W</u> , K444x, G446x	[8]
	(Konapreve <sup>+</sup> )	casirivimab (REGN10933)	<u>E406W</u> , F486x	
Celltrion	-	regdanvimab (CT-P59)	n.a.	n.a.

mAb type	age/se x (identif ier)	condition (treatments)	day mAb admins tered	other antiviral treatments	SARS- CoV-2 strain	Spike mutations	first detected at day	outcome	ref
REGN-CoV2 cocktail	45/M	antiphospholipid syndrome (steroids, rituximab, ruxolitinib, IVlg, cyclophosphamide)	45	remdesivir (5+10+5 days)	n.a.	E484K/A, Y489H, Q493K and N501Y	75	death	Choi <i>et al</i> [20] Clarke <i>et al</i> [21]
bamlanivimab monotherapy (700 mg iv)	n.a./n. a. (B2_11 )	immunocompetent	median 4.5	n.a.	n.a.	E484K	3 after mAb	n.a.	Choudhary et al [22]
	n.a./n. a. (B2_10 )			n.a.	n.a.	S494P	6 after mAb	n.a.	_
	n.a./n. a. (B2_8)			n.a.	n.a.	Е484К	4 after mAb	n.a.	
	n.a./n. a. (B2_7)	-		n.a.	n.a.	Е484К	6 after mAb	n.a.	
	n.a./n. a. (B2_6)			n.a.	n.a.	S494P +E484K (frequency <20%)	3 after mAb	n.a.	
	n.a./n. a.			n.a.	n.a.	E484Q	4 after mAb	n.a.	

# **Table 2**. Case reports of immune escape after anti-Spike mAb treatment.

(В	2_5)							-	
n.	a./n.		n.a.	n.a.	E484K	8 after mAb	n.a.		
a.									
(В	2_4)							-	
n.	a./n.		n.a.	n.a.	S494P	6 after mAb	n.a.		
a.									
(В	2_3)							-	
n.	a./n.		n.a.	n.a.	E484Q	3 after mAb	n.a.		+
a.									
(B	<u>2_2)</u>	4 (700			5404K J	6		<b>T</b> (C )	
12	2/M chronic lymphocyotic	4 (700	1 BNT16262 dose	Alpha	E484K and	6	recovered at day 61		
	hypegammaglobuling	mg)	20 days before		Q493K			[23]	erve
	mia (vonotoclay and								d. A
	rituyimab 17 days								o re
	earlier): steroids 21-26								use
55	5/F acute myeloid	14	Remdesivir davs	Alpha	F484K and	21	negative at day 51	Iohr <i>et al</i> l	241 d
	leukemia		23-27	, up no	Q493R.		negative at adj 51	Lonn oc un	i Aed
					S494P				Witt
70	D/M ANCA-associated	2	3 units of CCP at	B.1	E484K	12	died of MOF on day 20	Jensen <i>e</i>	t al 🛱
	vasculitis with end-		day 16		→E484Q,			[25]	perr
	stage renal disease				reverted to				niss
	(rituximab and				E484K after				ion.
	prednisolone)				ССР				
40	D/F AIDS	3	remdesivir and 2	B1.	E484K	10	recovered		
			units of CCP						
60	)/M relapsed follicular	76	2 CCP units on	B.1.17	E484K	87	recovered, negative at		
	lymphoma		day 57 and 1 CCP	7			day 103		
	(obinutuzumab,		unit on day 59						
	thiotepa, cytarabine,								
	etoposide)								

65/M	heart transplant	2	none	B 1 17	F484K	19	discharged at day 40	
05/11	recipient (about 30 years ago) (cyclosporine, azathioprine, prednisolone)	2		7		15	after 2 negative NPS	
65/M	chronic lymphatic leukemia	45	remdesivir and 3 units of CCP days 52-62, imdevimab/casiri vimab about day 70	B.1.25 8	E484K	52	recovered, negative at day 91	All right Bosel shift
33/M	Hodgkin lymphoma (untreated)	20	dexamethasone	B.1.36 2	$\begin{array}{rcl} \Delta F140 & \rightarrow \\ \Delta PFLGVY139-\\ 144, & G485R, \\ W258C \end{array}$	45	hospitalized for HL chemotherapy at end of follow-up	Bronstein <i>et al</i> 2 [26] za
68/M	chronic lymphocytic leukemia (FCR in 2017, prednisone for AIHA, venetoclax + rituximab in 2019)	10	CPP days 12 and 26, IVIg day 21, remdesivir days 37-41	Alpha	E484Q	22	discharged day 43	אוסא בע אות וסער הביו
n.a.	immunocompetent	2	n.a.	B.1.31 1	E484K	n.a.	resolved at home	Sabin <i>et al</i> [27]
87/M	immunocompetent	2	none	Alpha	E484K +S494P	6	discharged negative at day 27	Peiffer-Smadja <i>et al</i> [28]
35/M	Immunocompetent	2	none	Alpha	E484A/K	6	discharged, negative at day 38	
61/M	immunocompetent	2	steroids	Alpha	E484K	12	negative at day 8, hospitalized for unrelated reasons	
97/M	immunocompetent	4	none	Alpha	E484K	14	died at day 35 because	

	64/M	heart transplant recipient	2	corticosteroids for 10 days	Alpha	Q493R	26	of soft tissue infection discharged, negative at day 48	
oamlanivimab 700 mg + etesevimab	n.a.	n.a.	2	n.a.	n.a.	S494P	11	recovered, not detected in samples at day	Gottlieb <i>et al</i> [29]
400 mg ocktail	73/M	cholangiocarcinoma (steroids)	2	none	Alpha	Q493R	7	died day 18	Focosi <i>et al</i> [30]
	63/M	allogeneic HSCT recipient for mycosis fungoides	n.a.	none	Alpha	Q493R	15	discharged at day 2	Guigon <i>et al</i> [31]
	n.a.	solid organ transplantation	n.a.	none	Alpha	Q493R	7	n.a	Vellas <i>et al</i> [32]
	n.a.	solid organ transplantation	n.a.	none	Alpha	Q493R	7	n.a.	
	n.a.	solid organ transplantation	n.a.	none	Alpha	Q493R	14	n.a.	
	n.a.	solid organ transplantation	n.a.	none	Alpha	Q493K	7	n.a.	
	n.a.	solid organ transplantation	n.a.	none	Alpha	E484K	21	n.a.	
	34/F	B-ALL	<5 days	2 CCP units days 29-30	Alpha	Q493R	n.a.	all were rescued with CCP	Pommeret <i>et al</i> [33]
	62/F	Hodgkin lymphoma		1 CCP unit day 26	Alpha	Q493R	n.a.		
	63/F	follicular lymphoma	*	2 CCP units days 30-31	Alpha	Q493R	n.a.		
	67/F	follicular lymphoma		2 CCP units days 15-16	Alpha	n.a.	n.a.		
	57/M	chronic lymphocytic leukemia		2 CCP units days 30-31	Alpha	E484D	n.a.		

	preprint (which was not certified b	medRxiv preprint doi: https://doi
All rights reserved. No reuse allowed without permission.	y peer review) is the author/funder, who has granted medRxiv a license to display the preprint in per	i.org/10.1101/2021.11.11.21266207; this version posted November 11, 2021. The copyright holder for
	etuity.	this

121	Table 3. Case re	eports of immune	escape after CCF	vtreatment.
-----	------------------	------------------	------------------	-------------

age/sex (identifier)	condition	CCP schedule (and titer)	co-treatments	SARS- CoV-2 strain	Spike mutations	first detected at day	outcome	ref
71/F	chronic lymphocytic leukemia and iatrogenic hypogammaglobulinemia	70 (1:60) and 81 (1:160)	IVIG q4-6w	n.a.	ΔPFLGVYY139-145 ΔLGVY141-144	49 70 (poor causality)	negative NPS since day 105	Avanzato <i>et al</i> [34]
73/M	CAR-T-cell recipient	low titre days 2 and 58	remdesivir days 5- 10,63-74 dexamethasone days	GH	R190K and G1124D ΔY144, D215G, and N501T ΔH146	13 67 72	died day 74	Hensley <i>et al</i> [35]
70/M	B-cell depletion and hypogammaglobulinemia	63, 65, 102	remdesivir day 38- 48, 52-62 and 91- 101	n.a.	D796H and ∆HV69-70	57	died on day 102	Kemp <i>et al</i> [36]
21/M	B-acute lymphoblastic leukemia (CART tisagenlecleucel)	78, 103, 110, 123, 130, 137, 144, 158, 165, 172	remdesivir (2 5-days courses)	n.a.	3 major allele variants emerged between days 0 and 40 with an additional 4 major and 7 minor allele variants by day 144 (ΔLGV141- 143, ΔY145, ΔLGVY141-144, ΔNL211-212, N440K, V483A, and E484Q)	144	positive NPS at end of follow- up (day 250)	Truong <i>et al</i> [37]
50/M	kidney transplant recipient (tacrolimus, steroids)	1	tocilizumab day 2	B.1.369	Q493R, ΔAL243-244 had ~70% frequency; ΔLGVY141-144, E484K and Q493K had ~30%, ~20% and ~10%	21	died on day 94	Chen <i>et al</i> [38]

	<u>r</u>		T	1	r			T
					frequency			
75/M	B-CLL (FCR, ibrutinib)	2 units on day 70, 2 units on days 127- 128	remdesivir days 24- 33 and 60-64	n.a.	H49Y, ΔY144, ΔLLA241-243, ΔAL243-244, L242H, A243P, F490S, N1178N, and C1250F	80	still positive at end of follow-up (day 333)	Monrad <i>et al</i> [39]
60/M	mantle-cell lymphoma and associated B-cell immunodeficiency (rituximab, bispecific mAb, cyclophosphamide, doxorubicin, prednisone)	31, 122	remdesivir day 30 and 122	n.a.	mutations in ORF1a but not in Spike	n.a.	still positive at end of follow-up (day 156)	Baang <i>et al</i> [40] A∏ ngn tr ege P
40/F	diffuse large B-cell lymphoma (CART) and hypogammaglobulinemia	high-titer day 2, 313	IVIG, remdesivir day 2 and 313	B.1.332	∆LHR244-246 and A243G	313 (poor causation)	discharged day 324, cleared at day 335	Nussenblatt <i>et al</i> [41] (B B B B B B B B B B B B B B B B B B B
70/F (A)	follicular lymphoma (obinutuzumab-CHOP)	23, 34, 49, 55, 56, 62, 65, 70, 73, 77, 84, 86, 90, 94, 106	steroids	B.1.1.29	L18F, R682Q, ΔΥ144	50	died 5 months later	Khatamzas et al [42]
70/M	mantle cell lymphoma (R- BAC)	88	darunavir/ritonavir, hydroxychloroquine, methylprednisolone, tocilizumab days 1 78, remdesivir days 45-50 and 78-87, 180-184 and 210-	B.1.1	H69Y/P, V70G and S982A	238	died on day 271, still positive at day 268	Sepulcri <i>et al</i> [43]

			214, IVIg					
40/M	autologous hematopoietic	2 doses	IVIg	B.1.128	$\Delta$ LGV141-143 $\rightarrow$	134	negative	Mendes-Correa <i>et al</i>
	stem cell transplant due to	on days ?			ΔLGVY141-144		PCR on	[44]
	a DLBCL						day 196	

age/sex	condition	antiviral	SARS-	Spike mutations	first	outcome	ref
(identifier)		treatments	CoV-2		detected		
			strain		at day		
47/F	diffuse large B cell	n.a.	B.1.1.163	Y453F, ∆HV69-70,	120	negative PCR on day 132	Bazykin <i>et</i>
	lymphoma (rituximab plus			S50L, ∆LGVY141-144,			al [45]
	polychemotherapy)			T470N, and D737G			
61/F	diffuse large B cell	remdesivir for 10	B.1.1.401	V3G, S50L, N87S,	164	negative PCR at day 197	Borges et
	lymphoma stage IVB	days, high-dose		A222V,			<i>al</i> [46]
		steroids for 7		ΔLTTRTQLPPAYTN18-			
		days		30 and ∆LGVY141-144			
3/F (1)	B-cell acute lymphoblastic	n.a.	20C	silent l410l	27	negative PCR at day 91	Truong et
	leukemia (chemotherapy)			(22792:C/A)			al [37]
2/M (3)	B-cell acute lymphoblastic	remdesivir for 5	20C	V483A and E484Q	139	negative PCR at day 196	_
	leukemia	days		V70P, ΔLGV141-143,	162		
				N440K			
37/F	advanced HIV and	dexamethasone	B.1.1.273	E484K	6	negative at day 233	Karim <i>et al</i>
	antiretroviral treatment			K417T and F490S	71		[47]
	failure			L455F and F456L	106		
				D427Y and N501Y	190		
80/M	chronic lymphocytic	remdesivir days	B.52	L179	58	negative PCR day 311	Kavanagh
	leukemia and	213-230, REGN-		S255F, S477N, H655Y,	155		Williamson
	hypogammaglobulinemic	COV-2 day 265		D1620A, ∆HV69-70			et al [48]
40/M	autologous hematopoietic	IVIg	B.1.128	$\Delta$ LGV141-143 $\rightarrow$		negative PCR on day 196	Mendes-
	stem cell transplant due to			∆LGVY141-144			Correa <i>et</i>
	a DLBCL						al [44]
n.a./n.a.	transplant recipient	remdesivir	n.a.	S13I, T95I, E484G,	n.a.	n.a.	Weigang et
				F490L, ∆LGVY141-144,			<i>al</i> [49]
				$\Delta$ LHRS244-247, and			
				$\Delta$ SPRRARSV680-687			

**Table 4**. Intrahost variation in Spike sequence detected in immunocompromised patients not receiving nAb-based treatments.

	n.a./n.a.	18 B-cell non-Hodgkin	44% CCP	n.a.	n.a.	requested	n.a.	Lee <i>et al</i>
		lymphoma	37% remdesivir					[50]
л <sup>.</sup>		L	- <b>I</b> L					

### 125 Figure legends.

## **Figure 1.** PRISMA flow diagram of study selection.



#### 129 Figure 2.

130 Top panel) The full SARS-CoV-2 S (spike) glycoprotein homotrimer (PDBID 6VXX) [16] in the prefusion conformation is shown in surface representation, with each spike monomer colored a different shade of green. N-linked glycosylations which were resolved in the cryo-EM map in this structure (16/22 sequons 131 per protomer) are displayed as magenta sticks. The receptor binding domains (RBDs), in the closed state, are highlighted in 3 shades of blue corresponding 132 133 to the shade of the corresponding trimer. Escape mutations from case reports of patients treated with CCP are highlighted in orange. Spike mutations 134 associated with immune escape from clinically approved mAb treatments in vitro or from case reports are highlighted in red, while escape mutations 135 identified in both patients who received with clinically approved mAb treatments and CCP treatment are colored yellow. The full spike is shown oriented 136 along the long axis (left) and rotated 90 degrees to display mutations concentrated in the RBDs. Note that mutations located on unresolved loops on the 137 cryo-EM map of the full spike are not visualized (L18, V70, Y144, Y145, D146, R246, W258, G446, N460, I472, V483, E484, G485, F486, R682, N1178 and 138 C1250).

Bottom panel) A table summarizing escape mutations localized to the RBD resulting from mAb treatments in vitro and case reports, as well as from CCP

140 treatment. The crystal structure of single RBD domain (PBDID: 7BWJ)[17] from a more complete model (no missing loops) is displayed in surface view with

141 the secondary structure superimposed in cartoon representation. Each escape mutation residue is highlighted by coloration according to the legend to

right, and sidechains shown as sticks. In cases where a certain position corresponds to escape mutations from multiple treatments, the position is colored

143 white and the label includes asterisks with the colors corresponding to each treatment where the escape mutation was identified. All figures were

144 generated in PyMOL [18].



#### 146 Discussion

Escape from nAb based therapeutics provides a crucial demonstration that these immune therapies target protective antigens, which the pathogen actively evades. Hence, the emergence of neutralizing-resistant variants in individuals receiving mAb and CCP provides powerful evidence for their antiviral activity. This evidence is independent of reduction in viral load, which has been reported with mAbs given early in disease but have been an inconsistent finding in randomized controlled trials (RCT) of CCP for COVID-19 [51].

153 Getting frequencies for this phenomenon from case series is not possible due to the high risk of 154 selection biases, which would yield unrealistically high frequencies. In contrast, RCTs with their 155 control groups are the suggested reference. With bamlanivimab, there was no emergence of 156 resistance in the patients receiving 7000 mg, but resistance was reported in patients receiving 700 157 mg (8 cases: 7% vs 0% with placebo) [22]. Putative treatment-emergent bamlanivimab-resistant variants were detected in 7.1% of patients (7/98) in the 700 mg group, 9.8% of patients (10/102) in 158 159 the 2800 mg group, 11.3% of patients (11/97) in the 7000 mg group, 1% of patients (1/102) in the 160 bamlanivimab and etesevimab combination group, and in 4.8% of patients (7/145) in the placebo 161 group. The bamlanivimab monotherapy groups had a higher frequency of patients in whom a variant 162 was detected at more than 1 time point during the viral time course (4.1% for the 700 mg group, 163 5.9% for the 2800 mg group, and 7.2% for the 7000 mg group) than the placebo group or the 164 bamlanivimab and etesevimab combination group (both 0%) [29]. Apart from registration trials, the 165 largest case series to date evaluated the impact of mAbs on the nasopharyngeal (NP) viral load and 166 virus quasi-species of mAb-treated patients using single-molecule real-time sequencing after 167 bamlanivimab alone (4 patients), bamlanivimab/etesevimab (23 patients) and 168 casirivimab/Imdevimab (5 patients) [32]. To date a single case of immune escape has been reported 169 for the non-overlapping REGN-COV2 cocktail, and accordingly hamster models and clinical trials 170 showed no emergence of variants [52]. Since mAb therapy by definition targets only a single epitope 171 within the RBD, it is unsurprising that escape mutations observed after in vitro and in vivo selection 172 by these mAbs were single amino acid substitutions localized almost exclusively to the RBD (Figure 2, 173 bottom panel; Tables 1 and 2), as expected from *in vitro* studies with single mAb, but largely 174 prevented by non-overlapping mAb cocktails [53].

175 In contrast to mAb therapeutics, immune escape under CCP has not been investigated in RCTs. 176 Hence evidences exclusively stem from case series and case reports [54], and is further complicated 177 by exposure to multiple CCP units from different donors, each one having a polyclonal response at 178 differing titers and affinity. Unfortunately nAb titers were very rarely determined or reported, 179 precluding correlations between emergence of resistance and subneutralizing CCP doses. Overall, it 180 seems that escape variants from CCP selection have not been reported as commonly nor emerged as 181 fast. E.g., none out of 8 recipients of HSCT or CART who were treated with CCP and tested SARS-CoV-182 2-positive for 2 months showed significant mutations compared to the original strain [55]. Review of 183 the Spike protein changes associated with resistance after CCP therapy reveal that most of them had 184 in-frame amino acid deletions in a flexible region that is partially solvent exposed and forms a  $\beta$ 185 strand: plasticity may contribute to the structural permissibility of the identified deletions. The NTD 186 is a flexible region that can be affected by immune escape via either insertions (causing additional 187 glycosylation sites [11]) or recurrently deleted regions (RDR) ΔΗV69–70 (RDR1), ΔLGVY141–144 and 188 ΔD146 (RDR2), ΔI210 (RDR3) and ΔAL243–244 (RDR4) [56] : RDR1, RDR2 and RDR4 correspond to 189 NTD loops N2, N3 and N5, whereas RDR3 falls between N4 and N5.

191 Deletions of amino acids from a protein structure generally results in greater structural changes than 192 single amino acid changes, since these reduce the size of the protein and can trigger changes that 193 propagate through the whole structure. Furthermore, the mechanism for the emergence of deletion 194 variants appears to be very different from the single amino acid changes that are frequent from 195 error-prone RNA replication and could involve deletions from RNA editing. Since CCP targets a large 196 number of epitopes in the Spike protein while mAbs target a single epitope these molecular 197 differences parallel what is expected from their respective selection pressures in the sense that 198 escape from polyclonal preparations requires larger antigenic structural changes than escape from 199 mAbs. In contrast to escape mutations selected for by mAb therapy, CCP selection yields point 200 mutations throughout the Spike protein. This reflects the vast antigenic surface area covered by the 201 polyclonal antibodies within CCP. Escape mutations would be theoretically selected for on the basis 202 of the most potent antibodies present in a particular CCP unit, which may vary markedly from donor 203 to donor, which could explain the generally divergent evolution of SARS-CoV-2 in the presence of 204 CCP. However, residues 141-144 and 243-244 are the sites of mutations or deletions in several cases, 205 indicating these sites may offer effective escape from CCP derived from many donors, possibly by 206 triggering a large-scale conformational rearrangement, as discussed above. As RBD binding 207 antibodies are often neutralizing via ACE2 receptor occlusion, it is interesting that only 23% of CCP 208 case studies identified escape mutations within the RBD (Figure 2, top panel; Table 3). This suggests 209 that antibody binding to other sites on the Spike protein may have additional mechanisms of 210 neutralization (i.e., by preventing conformational change after ACE2 engagement), or that additional 211 antibody mediated immune responses (e.g., ADCC) are equally important as direct neutralization to 212 the antiviral response to SARS-CoV-2.

213 Nothing can be inferred about the fitness of an emerging mutant in the absence of selective 214 pressure, but it is of interest that one variant with the E484K mutant that emerged after 215 bamlanivimab therapy was able to infect multiple household contacts [27]. In vitro, several mutants 216 showed similar infectivity to wild type strain but resistance to different CCP donors [36]. In one 217 instance of immune escape associated with CCP, a variant with D796H mutation manifested 218 modestly reduced sensitivity to neutralization by CCP that was associated with reduced infectivity, 219 which was only partly compensated by  $\Delta$ HV69-70 [36]. Even if immune escape in registration trials 220 has been a rare phenomenon, it should be considered that in the real-world practice mAbs targeting 221 the SARS-CoV-2 Spike protein are being reserved for use in high-risk (immunocompromised) 222 patients. Considering the huge size of a pandemic, the likelihood of immune escape becomes 223 relevant, raising the possibility that rare variants with enhanced fitness could drive next pandemic 224 waves. Notably, several mutations have recurred in VOC and VOIs (e.g. E484K found in Beta and 225 Gamma, E484Q found in Delta, or  $\Delta$ LHR244-246 [41] found in VOI lambda), raising the possibility 226 that such variants emerged during treatment of patients (iatrogenic variants), but such inference will 227 likely remain very hard to prove. E406W mutation has never been reported in GISAID, and other 228 E406 mutations remain exceedingly rare (worldwide 318 cases of E406Q, 41 cases of E406D, and 2 229 cases each from USA for E406G, E406A, E406K, and 1 case of E406V out of 4,410,787 sequences 230 deposited in GISAID as of October 25, 2021). Similarly, Q493R has only been reported in 244 231 sequences and Q493K in 138 sequences (source: Outbreak.info). Lack of fixation of those mutation 232 facilitates the imputation that these require mAb selective pressure and/or effective infection 233 control techniques in the care of those patients prevented spill over to the general population.

Within host variation (so-called "quasi-species swarm") is a natural phenomenon which has been reported for SARS-CoV-2 in immunocompetent patients and ultimately facilitates persistence of infection. Among 33 patients having positive NPS PCR for an average of 18 days, Voloch *et al* observed a distinguishing pattern of mutations over the course of the infection mainly driven by increasing  $A \rightarrow U$  and decreasing  $G \rightarrow A$  signatures, including Spike mutations (V362L, T553I, H655Y, A688V, S691F, S884F, V1176F).  $G \rightarrow A$  mutations are driven by RNA-editing enzyme activities typical of innate immunity [57]. Nevertheless, several covariates can facilitate immune escape.

241 Immunosuppression has been postulated to be an accelerator for viral evolution. Actually, Table 4 242 shows that very few case reports have detailed intraclonal (within-host) evolution in patients 243 receiving immunosuppressive treatment, and, in the absence of nAb-based therapeutics, Spike 244 mutations rarely occurred [55].

245 On the other hand, co-administered small chemical antivirals can be mutagenic per se. Remdesivir 246 can adopt both amino and imino tautomeric conformations to base-pair with RNA bases [58]. Both 247 amino-remdesivir: G and imino-remdesivir: C pairs could be guite mutagenic. Serial in vitro passages 248 of SARS-CoV-2Engl2 in cell culture media supplemented with remdesivir selected for drug-resistant 249 viral populations. Remdesivir triggers the selection of SARS-CoV-2 variant with a E802D mutation in 250 the RdRp sufficient to confer decreased sensitivity to remdesivir without affecting viral fitness. The 251 analysis of more than 200,000 sequences also revealed the occurrence of 22 mutations in Spike, 252 including changes in amino acids E484 and N501 corresponding to mutations identified in Alpha and 253 Beta [59]. It has been hence been proposed than nAb-based therapeutics could amplify mutations 254 induced by remdesivir [3]. In this regard, Table 4 shows that many of the mAb- or CCP-associated 255 mutations emerged in individuals who were or had been treated with remdesivir (but neither mAbs 256 nor CCP), consistent with the notion that antiviral therapy could potentiate the emergence of 257 antibody-resistance mutations.

### 258 Conclusion

259 In summary, our survey of the available mutational data show that escape variants associated with 260 mAb and CCP therapy manifest different type of mutations. For mAbs most mutations are single 261 amino acid replacements in the RBD domain, while most variants eliciting in patients treated with 262 CCP exhibited amino acid deletions. In fact, it is noteworthy that RBD mutations were relatively rare 263 in CCP escape variants. Although the numbers are relatively small, which suggests cation in making 264 generalizations, this dichotomy in geography of mAb and CCP mutations could reflect the fact that 265 mAbs target a single epitope where the mAb-antigen interaction can be significantly altered by single amino acid changes while CCP targets many epitopes and has several mechanisms of action, 266 267 such that evading polyclonal antibody immunity is likely to require much larger Spike protein 268 structural changes. Despite the relatively small set of variants for which there is molecular data 269 available, the large variation of molecular solutions that allow SARS-CoV-2 to escape antibody-270 mediated protection is striking and suggest the need for continued vigilance in genomic surveillance, 271 especially in cases refractory to therapy.

272 We declare we don't have any conflict of interest related to this manuscript.

273

### 274 References

275	1.	Van Egeren, D.; Novokhodko, A.; Stoddard, M.; Tran, U.; Zetter, B.; Rogers, M.; Pentelute, B.
276		L.; Carlson, J. M.; Hixon, M. S.; Joseph-McCarthy, D.; Chakravarty, A., Risk of evolutionary
277		escape from neutralizing antibodies targeting SARS-CoV-2 spike protein. <b>2020</b> ,
278		2020.11.17.20233726.
279	2.	Landis, J.; Moorad, R.; Pluta, L. J.; Caro-Vegas, C.; McNamara, R. P.; Eason, A. B.; Bailey, A.;
280		Villamor, F. C. S.; Juarez, A.; Wong, J. P.; Yang, B.; Broussard, G. S.; Damania, B.; Dittmer, D.,

201		later hast such that a second a second success of CADC CoV 2 second sets 2021
201		Intra-nost evolution provides for continuous emergence of SARS-COV-2 variants. <b>2021</b> ,
282	2	
283	3.	Colson, P.; Devaux, C. A.; Lagier, J. C.; Gautret, P.; Raouit, D., A Possible Role of Remdesivir
284		and Plasma Therapy in the Selective Sweep and Emergence of New SARS-Cov-2 Variants.
285		Journal of clinical medicine <b>2021,</b> 10, (15).
286	4.	Kabinger, F.; Stiller, C.; Schmitzova, J.; Dienemann, C.; Hillen, H. S.; Hobartner, C.; Cramer, P.,
287	_	Mechanism of molnupiravir-induced SARS-CoV-2 mutagenesis. <b>2021</b> , 2021.05.11.443555.
288	5.	Starr, T. N.; Greaney, A. J.; Hilton, S. K.; Ellis, D.; Crawford, K. H. D.; Dingens, A. S.; Navarro,
289		M. J.; Bowen, J. E.; Tortorici, M. A.; Walls, A. C.; King, N. P.; Veesler, D.; Bloom, J. D., Deep
290		Mutational Scanning of SARS-CoV-2 Receptor Binding Domain Reveals Constraints on Folding
291		and ACE2 Binding. <i>Cell</i> <b>2020,</b> 182, (5), 1295-1310.e20.
292	6.	Greaney, A. J.; Starr, T. N.; Gilchuk, P.; Zost, S. J.; Binshtein, E.; Loes, A. N.; Hilton, S. K.;
293		Huddleston, J.; Eguia, R.; Crawford, K. H. D.; Dingens, A. S.; Nargi, R. S.; Sutton, R. E.;
294		Suryadevara, N.; Rothlauf, P. W.; Liu, Z.; Whelan, S. P. J.; Carnahan, R. H.; Crowe, J. E., Jr.;
295		Bloom, J. D., Complete Mapping of Mutations to the SARS-CoV-2 Spike Receptor-Binding
296		Domain that Escape Antibody Recognition. Cell host & microbe 2020.
297	7.	Javanmardi, K.; Chou, CW.; Terrace, C.; Annapareddy, A.; Kaoud, T. S.; Guo, Q.; Lutgens, J.;
298		Zorkic, H.; Horton, A. P.; Gardner, E. C.; Nguyen, G.; Boutz, D. R.; Goike, J.; Voss, W. N.; Kuo,
299		HC.; Dalby, K. N.; Gollihar, J. D.; Finkelstein, I. J., Rapid characterization of spike variants via
300		mammalian cell surface display. <b>2021</b> , 2021.03.30.437622.
301	8.	Starr, T. N.; Greaney, A. J.; Addetia, A.; Hannon, W. W.; Choudhary, M. C.; Dingens, A. S.; Li, J.
302		Z.; Bloom, J. D., Prospective mapping of viral mutations that escape antibodies used to treat
303		COVID-19. Science 2021, eabf9302.
304	9.	Starr, T. N.; Greaney, A. J.; Dingens, A. S.; Bloom, J. D., Complete map of SARS-CoV-2 RBD
305		mutations that escape the monoclonal antibody LY-CoV555 and its cocktail with LY-CoV016.
306		Cel Reports Medicine <b>2021.</b> 2, (4), 100255.
307	10.	Garrett, M. E.: Galloway, J.: Chu, H. Y.: Itell, H. L.: Stoddard, C. I.: Wolf, C. R.: Logue, J. K.:
308		McDonald, D.: Matsen, F. A.: Overbaugh, J., High resolution profiling of pathways of escape
309		for SARS-CoV-2 spike-binding antibodies. <i>bioRxiv</i> <b>2020</b> .
310	11.	Andreano, F.; Piccini, G.; Licastro, D.; Casalino, I.; Johnson, N. V.; Paciello, I.; Dal Monego, S.;
311		Pantano, E.: Manganaro, N.: Manenti, A.: Manna, R.: Casa, F.: Hyseni, I.: Benincasa, I.:
312		Montomoli E : Amaro R E : McLellan I S : Rappuoli R SARS-CoV-2 escape in vitro from a
313		highly neutralizing COVID-19 convalescent plasma. <i>Proceedings of the National Academy of</i>
314		Sciences of the United States of America <b>2020</b> 118 (36) e2103154118
315	12	Wang 7 : Schmidt E : Weishlum Y : Muecksch E : Barnes C O : Finkin S : Schaefer-
316	12.	Bahajew D: Cinolla M: Gaebler C: Lieberman I.A: Vang 7: Abernathy M.E: Huev-
317		Tuhman K E Hurley A : Turroia M : West K A : Gordon K : Millard K G : Ramos V : Silva
318		LD: Yu L: Colhert R. A.: Patel R: Dizon LP: Unson-O'Brian C: Shimeliovich L:
310		Gazumvan A.: Caskev M.: Biorkman P. L.: Casellas R.: Hatzijoannou T.: Bienjasz P. D.:
320		Nussenzweig M. C. mRNA vaccine-alicited antibodies to SARS-CoV-2 and circulating variants
221		https://www.biorviv.org/content/biorviv/corly/2021/01/19/2021 01 15 426911 full pdf
221	10	Considered A Handerson H. Joyner M. Direfeld L. S. SARS Cov2 verients and convolusiont
222	15.	casadevali, A., Henderson, J., Joyner, W., Phorski, La., SARS-Cov2 valiants and convalescent
525 224	14	Valesana, A. L. Bumfalt, K. E. Dimshaff, D. E. Blair, C. N. Fitzsimmons, W. L. Batria, L. C.
324 275	14.	Valesano, A. L., Ruillell, R. E., Dilliciell, D. E., Dialf, C. N., Filzsillinoits, W. J., Petrie, J. G.; Martin, E. T. Lauring, A. S. Tomporal dynamics of SABS CoV 2 mutation accumulation within
325		martin, E. T.; Lauring, A. S., Temporal dynamics of SARS-Cov-2 mutation accumulation within
5∠0 227	1 🗆	anu across infected nosts. <b>2021</b> , 2021.01.19.427330.
327	15.	Page, IVI. J.; IVICKENZIE, J. E.; BOSSUYT, P. M.; BOUTION, I.; Hoffmann, T. C.; Mulrow, C. D.;
328 220		snamseer, L.; Tetziam, J. WI.; Aki, E. A.; Brennan, S. E.; Chou, K.; Glanville, J.; Grimshaw, J. M.;
329		Hrobjartsson, A.; Lalu, M. M.; Li, I.; Loder, E. W.; Mayo-Wilson, E.; McDonald, S.;
330		McGuinness, L. A.; Stewart, L. A.; Thomas, J.; Tricco, A. C.; Welch, V. A.; Whiting, P.; Moher,

331 332		D., The PRISMA 2020 statement: an updated guideline for reporting systematic reviews.
333	16	Walls A. C. Park Y. L. Tortorici, M. A. Wall, A. McGuire, A. T. Veesler, D. Structure
334	10.	Function and Antigenicity of the SARS-CoV-2 Spike Glycoprotein <i>Cell</i> <b>2020</b> , 181 (2) 281-
335		292.e6.
336	17.	Ju. B.: Zhang, O.: Ge. J.: Wang, R.: Sun, J.: Ge. X.: Yu. J.: Shan, S.: Zhou, B.: Song, S.: Tang, X.:
337		Yu I'lan I'Yuan I'Wang H'7hao I'7hang S'Wang Y'Shi X'liu I'7hao I'Wang
338		X.: Zhang, Z.: Zhang, L., Human neutralizing antibodies elicited by SARS-CoV-2 infection.
339		Nature <b>2020.</b> 584, (7819), 115-119.
340	18.	The PyMOL Molecular Graphics System, Version 2.4.1 Schrödinger, LLC.
341	19.	Wang, P.; Nair, M. S.; Lihong, L.; Iketani, S.; Luo, Y.; Guo, Y.; Wang, M.; Yu, J.; Zhang, B.;
342		Kwong, P. D.; Graham, B. S.; Mascola, J. R.; Chang, J. Y.; Yin, M. T.; Sobieszczyk, M. E.;
343		Kyratsous, C. A.; Shapiro, L.; Sheng, Z.; Huang, Y.; Ho, D. D., Antibody resistance of SARS-CoV-
344		2 variants B.1.351 and B.1.1.7. <i>Nature</i> <b>2021,</b> 593, 130-135.
345	20.	Choi, B.; Choudhary, M. C.; Regan, J.; Sparks, J. A.; Padera, R. F.; Qiu, X.; Solomon, I. H.; Kuo,
346		HH.; Boucau, J.; Bowman, K.; Adhikari, U. D.; Winkler, M. L.; Mueller, A. A.; Hsu, T. YT.;
347		Desjardins, M.; Baden, L. R.; Chan, B. T.; Walker, B. D.; Lichterfeld, M.; Brigl, M.; Kwon, D. S.;
348		Kanjilal, S.; Richardson, E. T.; Jonsson, A. H.; Alter, G.; Barczak, A. K.; Hanage, W. P.; Yu, X. G.;
349		Gaiha, G. D.; Seaman, M. S.; Cernadas, M.; Li, J. Z., Persistence and Evolution of SARS-CoV-2
350		in an Immunocompromised Host. <b>2020,</b> 383, (23), 2291-2293.
351	21.	Clark, S. A.; Clark, L. E.; Pan, J.; Coscia, A.; McKay, L. G. A.; Shankar, S.; Johnson, R. I.; Brusic,
352		V.; Choudhary, M. C.; Regan, J.; Li, J. Z.; Griffiths, A.; Abraham, J., SARS-CoV-2 evolution in an
353		immunocompromised host reveals shared neutralization escape mechanisms. Cell 2021,
354		184, (10), 2605-2617.e18.
355	22.	Choudhary, M. C.; Chew, K. W.; Deo, R.; Flynn, J. P.; Regan, J.; Crain, C. R.; Moser, C.; Hughes,
356		M.; Ritz, J.; Ribeiro, R. M.; Ke, R.; Dragavon, J. A.; Javan, A. C.; Nirula, A.; Klekotka, P.;
357		Greninger, A. L.; Fletcher, C. V.; Daar, E. S.; Wohl, D. A.; Eron, J. J.; Currier, J. S.; Parikh, U. M.;
358		Sieg, S. F.; Perelson, A. S.; Coombs, R. W.; Smith, D. M.; Li, J. Z., Emergence of SARS-CoV-2
359		Resistance with Monoclonal Antibody Therapy. <i>medRxiv</i> 2021.
360	23.	Truffot, A.; Andreani, J.; Le Marechal, M.; Caporossi, A.; Epaulard, O.; Poignard, P.; Sylvie, L.,
361		SARS-CoV-2 Variants in Immunocompromised Patient Given Antibody Monotherapy.
362		Emerging infectious diseases <b>2021,</b> 27, (10).
363	24.	Lohr, B.; Niemann, D.; Verheyen, J., Bamlanivimab treatment leads to rapid selection of
364		immune escape variant carrying E484K mutation in a B.1.1.7 infected and
365		immunosuppressed patient. Clinical infectious diseases : an official publication of the
366	25	Infectious Diseases Society of America 2021.
367	25.	Jensen, B.; Luebke, N.; Feldt, T.; Keltel, V.; Brandenburger, T.; Kindgen-Willes, D.; Lutterbeck,
368		M.; Freise, N. F.; Schöeler, D.; Haas, R.; Diltney, A.; Adams, O.; Walker, A.; Timm, J.; Luedde,
369		T., Emergence of the E484K mutation in SARS-COV-2-infected immunocompromised patients
370	20	Brenetein V. Adler, A. Ketech, H. Helutz, O. V. H. Lewitzlari, K. Evolution of aniko
3/1 272	20.	Bronstein, Y.; Adier, A.; Katash, H.; Halutz, O.; Y, H.; Levytskyl, K., Evolution of spike
572 272		noreistont COVID 19 infection Journal of medical virology <b>2021</b>
27/	27	Sabin A. B.: Pichmond C. S.: Konny, P. A. Acquisition and onward transmission of a SAPS
374	27.	CoV-2 E484K variant among household contacts of a hamlanivimab-treated nations. <b>2021</b>
376		2021 10 02 21264415
377	28	Peiffer-Smadia N · Bridier-Nahmias A · Ferré V/ M · Charpentier C · Garé M · Bioux C ·
378	20.	Allemand, A.; Lavallée, P.; Ghosn, J.; Kramer, L.; Descamps, D.; Vazdannanah, V.; Visseaux, B.
379		Emergence of E484K Mutation Following Bamlanivimab Monotherapy among High-Risk
380		Patients Infected with the Alpha Variant of SARS-CoV-2. Viruses <b>2021</b> , 13, (8).
-		

381 382 383 384 385 386	29.	Gottlieb, R. L.; Nirula, A.; Chen, P.; Boscia, J.; Heller, B.; Morris, J.; Huhn, G.; Cardona, J.; Mocherla, B.; Stosor, V.; Shawa, I.; Kumar, P.; Adams, A. C.; Van Naarden, J.; Custer, K. L.; Durante, M.; Oakley, G.; Schade, A. E.; Holzer, T. R.; Ebert, P. J.; Higgs, R. E.; Kallewaard, N. L.; Sabo, J.; Patel, D. R.; Klekotka, P.; Shen, L.; Skovronsky, D. M., Effect of Bamlanivimab as Monotherapy or in Combination With Etesevimab on Viral Load in Patients With Mild to Moderate COVID-19: A Bandomized Clinical Trial. <i>IAMA</i> <b>2021</b> , 325 (7) 632-644
387 388 389	30.	Focosi, D.; Novazzi, F.; Genoni, A.; Dentali, F.; Dalla Gasperina, D.; Baj, A.; Maggi, F., Daniele Focosi, Federica Novazzi, Angelo Genoni, Francesco Dentali, Daniela Dalla gasperina, Andreina Bai, Fabrizio Maggi, <b>2021</b>
390 391 392 393	31.	Guigon, A.; Faure, E.; Lemaire, C.; Chopin, M.; Tinez, C.; Assaf, A.; Lazrek, M.; Hober, D.; Bocket, L.; Engelmann, I.; Kazali Alidjinou, E., Emergence of Q493R mutation in SARS-CoV-2 spike protein during bamlanivimab/etesevimab treatment and resistance to viral clearance. J Infact <b>2021</b> , S0163-4453, (21), 00435-7
394 395 396 397	32.	Vellas, C.; Del Bello, A.; Alexa, D.; Steinmeyer, Z.; Tribaudeau, L.; Ranger, N.; Jeanne, N.; Martin-Blondel, G.; Delobel, P.; Kamar, N.; Izopet, J., Influence of neutralizing monoclonal antibodies on the SARS-CoV-2 quasispecies in patients with COVID-19. <i>Clin Microb Infect</i> <b>2021</b> .
398 399 400 401 402	33.	Pommeret, F.; Colomba, J.; Bigenwald, C.; Laparra, A.; Bockel, S.; Bayle, A.; Michot, J. M.; Hueso, T.; Albiges, L.; Tiberghien, P.; Marot, S.; Jary, A.; Lacombe, K.; Barlesi, F.; Griscelli, F.; Colomba, E., Bamlanivimab+ etesevimab therapy induces SARS-CoV-2 immune escape mutations and secondary clinical deterioration in COVID-19 patients with B-cell malignancies. <i>Annals of Oncology</i> <b>2021</b>
403 404 405 406	34.	Avanzato, V. A.; Matson, M. J.; Seifert, S. N.; Pryce, R.; Williamson, B. N.; Anzick, S. L.; Barbian, K.; Judson, S. D.; Fischer, E. R.; Martens, C.; Bowden, T. A.; de Wit, E.; Riedo, F. X.; Munster, V. J., Case Study: Prolonged Infectious SARS-CoV-2 Shedding from an Asymptomatic Immunocompromised Individual with Cancer. <i>Cell</i> <b>2020</b> .
407 408 409 410 411 412 413 414	35.	Hensley, M. K.; Bain, W. G.; Jacobs, J.; Nambulli, S.; Parikh, U.; Cillo, A.; Staines, B.; Heaps, A.; Sobolewski, M. D.; Rennick, L. J.; Macatangay, B. J. C.; Klamar-Blain, C.; Kitsios, G. D.; Methé, B.; Somasundaram, A.; Bruno, T.; Cardello, C.; Shan, F.; Workman, C.; Ray, P.; Ray, A.; Lee, J.; Sethi, R.; Schwarzmann, W. E.; Ladinsky, M. S.; Bjorkman, P. J.; Vignali, D. A.; Duprex, W. P.; Agha, M. E.; Mellors, J. W.; McCormick, K. D.; Morris, A.; Haidar, G., Intractable COVID-19 and Prolonged SARS-CoV-2 Replication in a CAR-T-cell Therapy Recipient: A Case Study. <i>Clinical infectious diseases : an official publication of the Infectious Diseases Society of</i> <i>America</i> <b>2021</b> .
415 416 417 418 419 420	36.	Kemp, S. A.; Collier, D. A.; Datir, R.; Gayed, S.; Jahun, A.; Hosmillo, M.; Ferreira, I. A.; Rees- Spear, C.; Mlcochova, P.; Lumb, I. U.; Roberts, D.; Chandra, A.; Temperton, N.; Sharrocks, K.; Blane, E.; Briggs, J. A.; Smith, K. G.; Bradley, J. R.; Smith, C.; Goldstein, R.; Goodfellow, I. G.; Smielewska, A.; Skittrall, J. P.; Gouliouris, T.; Gkrania-Klotsas, E.; Illingworth, C. J.; McCoy, L. E.; Gupta, R. K., Neutralising antibodies in Spike mediated SARS-CoV-2 adaptation. <i>Nature</i> <b>2020</b> , 2020.12.05.20241927.
421 422 423 424 425 426	37.	Truong, T. T.; Ryutov, A.; Pandey, U.; Yee, R.; Goldberg, L.; Bhojwani, D.; Aguayo-Hiraldo, P.; Pinsky, B. A.; Pekosz, A.; Shen, L.; Boyd, S. D.; Wirz, O. F.; Roltgen, K.; Bootwalla, M.; Maglinte, D. T.; Ostrow, D.; Ruble, D.; Han, J. H.; Biegel, J. A.; Li, M.; Huang, C.; Sahoo, M. K.; Pannaraj, P. S.; O'Gorman, M.; Judkins, A. R.; Gai, X.; Dien Bard, J., Persistent SARS-CoV-2 infection and increasing viral variants in children and young adults with impaired humoral immunity. <i>EBioMedicine</i> <b>2021</b> , 67, 103355.
427 428 429 430 431	38.	Chen, L.; Zody, M. C.; Mediavilla, J. R.; Cunningham, M. H.; Composto, K.; Chow, K. F.; Kordalewska, M.; Corvelo, A.; Oschwald, D. M.; Fennessey, S.; Zetkulic, M.; Dar, S.; Kramer, Y.; Mathema, B.; Maniatis, T.; Perlin, D. S.; Kreiswirth, B. N., Emergence of multiple SARS- CoV-2 antibody escape variants in an immunocompromised host undergoing convalescent plasma treatment. <i>mSphere</i> <b>2021</b> , 6, (4), e0048021.

432	39.	Monrad, I.; Sahlertz, S. R.; Nielsen, S. S. F.; Pedersen, L.; Petersen, M. S.; Kobel, C. M.;
433		Tarpgaard, I. H.; Storgaard, M.; Mortensen, K. L.; Schleimann, M. H.; Tolstrup, M.; Vibholm,
434		L. K., Persistent Severe Acute Respiratory Syndrome Coronavirus 2 Infection in
435		Immunocompromised Host Displaying Treatment Induced Viral Evolution. Open forum
436		infectious diseases <b>2021,</b> 8, (7), ofab295.
437	40.	Baang, J. H.; Smith, C.; Mirabelli, C.; Valesano, A. L.; Manthei, D. M.; Bachman, M. A.; Wobus,
438		C. E.; Adams, M.; Washer, L.; Martin, E. T.; Lauring, A. S., Prolonged Severe Acute Respiratory
439		Syndrome Coronavirus 2 Replication in an Immunocompromised Patient. J Infect Dis 2021,
440		223, (1), 23-27.
441	41.	Nussenblatt, V.; Roder, A.; Das, S.; de Wit, E.; Youn, JH.; Banakis, S.; Muchegian, A.;
442		Mederos, C.; Wang, W.; Chung, M.; Perez-Perez, L.; Palmore, T.; Brudno, J.; Kochenderfer, J.;
443		Ghedin, E., Year-long COVID-19 infection reveals within-host evolution of SARS-CoV-2 in a
444		patient with B cell depletion. <b>2021</b> , 2021.10.02.21264267.
445	42.	Khatamzas, E.; Rehn, A.; Muenchhoff, M.; Hellmuth, J.; Gaitzsch, E.; Weiglein, T.; Georgi, E.;
446		Scherer, C.; Stecher, S.; Weigert, O.; Girl, P.; Zange, S.; Keppler, O. T.; Stemmler, J.; von
447		Bergwelt-Baildon, M.; Wölfel, R.; Antwerpen, M., Emergence of multiple SARS-CoV-2
448		mutations in an immunocompromised host. <b>2021</b> , 2021.01.10.20248871.
449	43.	Sepulcri, C.; Dentone, C.; Mikulska, M.; Bruzzone, B.; Lai, A.; Fenoglio, D.; Bozzano, F.;
450		Bergna, A.; Parodi, A.; Altosole, T.; Delfino, E.; Bartalucci, G.; Orsi, A.; Di Biagio, A.; Zehender,
451		G.; Ballerini, F.; Bonora, S.; De Palma, R.; Silvestri, G.; De Maria, A.; Bassetti, M., The longest
452		persistence of viable SARS-CoV-2 with recurrence of viremia and relapsing symptomatic
453		COVID-19 in an immunocompromised patient – a case study. <i>Open forum infectious diseases</i>
454		<b>2021,</b> ofab217, 2021.01.23.21249554.
455	44.	Mendes-Correa, M. C.; Ghilardi, F.; Salomao, M. C.; Villas-Boas, L. S.; Vincente de Paula, A.;
456		Tozetto-Mendoza, T. R.; Freire, W.; Sales, F. C. d. S.; Romano, C. M.; Claro, I. M.; de Souza, L.
457		M.; Ramos, J. F.; Paiao, H. G. d. O.; Szor, R. S., SARS-CoV-2 shedding, infectivity and evolution
458		in an immunocompromised adult patient. <b>2021</b> , 2021.06.11.21257717.
459	45.	Bazykin, G.; Stanevich, O.; Danilenko, D.; Fadeev, A.; Komissarova, K.; Ivanova, A.; Sergeeva,
460		M.; Safina, K.; Nabieva, E.; Klink, G.; Garushyants, S.; Zabutova, J.; Kholodnaia, A.; Skorokhod,
461		L; Ryabchikova, V.; Komissarov, A.; Lioznov, D. Emergence of Y453F and $\Delta 69$ -70HV mutations
462		in a lymphoma patient with long-term COVID-19. https://virological.org/t/emergence-of-
463	10	y4531-and-69-70nv-mutations-in-a-lymphoma-patient-with-long-term-covid-19/580
464	46.	Borges, V.; Islaro, J.; Cunna, M.; Cochicho, D.; Martins, L.; Banna, L.; Figueiredo, M.; Rebeio,
465		L.; Trindade, M.; Duarte, S.; Vieira, L.; Alves, M.; Costa, I.; Gulomar, R.; Santos, M.; Corte-
400		Real, R.; Dias, A.; Povoas, D.; Cabo, J.; Figueiredo, C.; Manata, M.; Maitez, F.; da Silva, M.;
407		Hodgkin lumphomo. mSphere <b>2021</b> , e0024421
400	17	Hougkin lympholina. Inspirere 2021, e0024421.
409	47.	E : San E L : Msomi N : Misana K : Khan K : Bornstoin M : Maniskshund Nithondra N :
470		Singh L. Bannhal H. Hangkom W. Lessells R. L. Sigal A. de Oliveira T. Persistent SARs-
471		CoV-2 infection and intra-bost evolution in association with advanced HIV infection <b>2021</b>
472		
475	18	ZUZI.00.03.21230228. Kavanagh Williamson M : Hamilton E : Hutchings S : Pymont H M : Hackett M : Arnold
475	40.	D: Maskell N: MacGowan A P: Albur m: Jenkins M: Heys J: Knanner F: Elsaved M:
476		Milligan R · Muir P · Vinond B · Matthews D A · Moran E · Davidson A D D. Chronic
477		SARS-CoV-2 infection and viral evolution in a hypogammaglobulingemic individual <b>2021</b>
478		2021.05.31.21257591.
479	49.	Weigang, S.; Fuchs, J.; Zimmer, G.; Schnepf, D.: Kern. L.: Beer. J.: Luxenburger. H.: Ankerhold.
480		J.; Falcone, V.; Kemming, J.; Hofmann, M.; Thimme, R.; Neumann-Haefelin, C.; Ulferts. S.:
481		Grosse, R.; Hornuss, D.; Tanriver, Y.; Rieg, S.; Wagner, D.; Huzly, D.; Schwemmle, M.:

482		Panning, M.; Kochs, G., Within-host evolution of SARS-CoV-2 in an immunosuppressed
483		COVID-19 patient: a source of immune escape variants. <b>2021</b> , 2021.04.30.21256244.
484	50.	Lee, C. Y.; Shah, M. K.; Hoyos, D.; Solovyov, A.; Douglas, M.; Taur, Y.; Maslak, P. G.; Babady,
485		N. E.; Greenbaum, B.; Kamboj, M.; Vardhana, S. A., Prolonged SARS-CoV-2 infection in
486		patients with lymphoid malignancies. <b>2021</b> , 2021.08.25.21262417.
487	51.	Focosi, D.; Franchini, M.; Pirofski, L. A.; Maggi, F.; Casadevall, A., Is SARS-CoV-2 viral
488		clearance in nasopharyngal swabs an appropriate surrogate marker for clinical efficacy of
489		neutralizing antibody-based therapeutics? <i>Rev Med Virol</i> <b>2021</b> .
490	52.	Copin, R.; Baum, A.; Wloga, E.; Pascal, K. E.; Giordano, S.; Fulton, B. O.; Zhou, A.; Negron, N.;
491		Lanza, K.; Chan, N.; Coppola, A.; Chiu, J.; Ni, M.; Atwal, G. S.; Romero Hernandez, A.;
492		Saotome, K.; Zhou, Y.; Franklin, M. C.; Hooper, A. T.; McCarthy, S.; Hamon, S.; Hamilton, J. D.;
493		Staples, H. M.; Alfson, K.; Carrion, R.; Ali, S.; Norton, T.; Somersan-Karakaya, S.;
494		Sivapalasingam, S.; Herman, G. A.; Weinreich, D. M.; Lipsich, L.; Stahl, N.; Murphy, A. J.;
495		Yancopoulos, G. D.; Kyratsous, C. A., REGEN-COV protects against viral escape in preclinical
496		and human studies. <i>bioRxiv [Preprint]</i> <b>2021</b> , 2021.03.10.434834.
497	53.	Baum, A.; Fulton, B. O.; Wloga, E.; Copin, R.; Pascal, K. E.; Russo, V.; Giordano, S.; Lanza, K.;
498		Negron, N.; Ni, M.; Wei, Y.; Atwal, G. S.; Murphy, A. J.; Stahl, N.; Yancopoulos, G. D.;
499		Kyratsous, C. A., Antibody cocktail to SARS-CoV-2 spike protein prevents rapid mutational
500		escape seen with individual antibodies. <b>2020,</b> 369, (6506), 1014-1018.
501	54.	Harvey, W. T.; Carabelli, A. M.; Jackson, B.; Gupta, R. K.; Thomson, E. C.; Harrison, E. M.;
502		Ludden, C.; Reeve, R.; Rambaut, A.; Peacock, S. J.; Robertson, D. L.; Consortium, CG. U.,
503		SARS-CoV-2 variants, spike mutations and immune escape. <i>Nature Reviews Microbiology</i>
504		<b>2021,</b> 19, (7), 409-424.
505	55.	Aydillo, T.; Gonzalez-Reiche, A. S.; Aslam, S.; van de Guchte, A.; Khan, Z.; Obla, A.; Dutta, J.;
506		van Bakel, H.; Aberg, J.; García-Sastre, A.; Shah, G.; Hohl, T.; Papanicolaou, G.; Perales, MA.;
507		Sepkowitz, K.; Babady, N. E.; Kamboj, M., Shedding of Viable SARS-CoV-2 after
508		Immunosuppressive Therapy for Cancer. <b>2020,</b> 383, (26), 2586-2588.
509	56.	McCarthy, K. R.; Rennick, L. J.; Nambulli, S.; Robinson-McCarthy, L. R.; Bain, W. G.; Haidar, G.;
510		Duprex, W. P., Recurrent deletions in the SARS-CoV-2 spike glycoprotein drive antibody
511		escape. <i>Science</i> <b>2021,</b> 371, (6534), 1139-1142.
512	57.	Voloch, C. M.; da Silva Francisco Jr, R.; de Almeida, L. G. P.; Brustolini, O. J.; Cardoso, C. C.;
513		Gerber, A. L.; Guimarães, A. P. d. C.; Leitão, I. d. C.; Mariani, D.; Ota, V. A.; Lima, C. X.;
514		Teixeira, M. M.; Dias, A. C. F.; Galliez, R. M.; Faffe, D. S.; Porto, L. C.; Aguiar, R. S.; Castiñeira,
515		T. M. P. P.; Ferreira, O. C.; Tanuri, A.; de Vasconcelos, A. T. R., Intra-host evolution during
516		SARS-CoV-2 prolonged infection. <i>Virus Evolution</i> <b>2021,</b> 7, (2).
51/	58.	Singh, V.; Fedeles, B. I.; Essigmann, J. M., Role of tautomerism in RNA biochemistry. RNA
518	-0	(New York, N.Y.) <b>2015,</b> 21, (1), 1-13.
519	59.	Szemiel, A. M.; Merits, A.; Orton, R. J.; MacLean, O.; Pinto, R. M.; Wickenhagen, A.; Lieber,
520		G.; Turnbull, IVI. L.; Wang, S.; IVIAIR, D.; da SIVA FIIIPE, A.; WIIIett, B. J.; Wilson, S. J.; Patel, A.
521		n., momson, E. C.; Palmanni, W.; Koni, A.; Stewart, W. E., <em>in vitro</em> evolution of
522		Remuesivit resistance reveals genome plasticity of SARS-COV-2. <b>2021</b> , 2021.02.01.429199.
523		